

# American Recovery and Reinvestment (ARRA)

## “Shovel-ready” Concepts

- Announcement: NCI Activities to Promote Research Collaboration
- RFA Concept: AIDS Vaccine Program

February 26, 2009

# American Recovery and Reinvestment Initiatives (ARRA)

**ANNOUNCEMENT:**

**NCI ACTIVITIES TO PROMOTE RESEARCH  
COLLABORATIONS**

## Announcement: NCI Activities to Promote Research Collaboration (APRC)

Purpose: To stimulate new, multidisciplinary research collaborations across the cancer research continuum

Criteria:

- Both the proposed project and the collaboration must be novel
- All collaborators must be funded by peer-reviewed mechanisms

Mechanism:

- Administrative supplements to NCI-funded grants
- Eligible mechanisms: P01, P20, P25, R01, R33, R37, U01, U10, U19, or U54/56

Funding:

- \$15M (\$7.5M/year for 2 years)
- \$100k d.c./\$300k d.c. (per consortia max) per year up to 2 years
- ~12-15 supplements to existing NCI grants
- April 15, 2009 receipt date/June 1, 2009 funding date

# American Recovery and Reinvestment Initiatives (ARRA)

**RFA:**

**Development of Vaccines against  
HIV-associated Malignancies or HIV Infections**

## Development of Vaccines against HIV-associated Malignancies or HIV Infections

Purpose: To stimulate research in either preventative or therapeutic vaccine development against HIV and HIV-associated viral malignancies

Examples of viruses implicated in HIV-associated cancers:

- KSHV/HHV8
- EBV
- HCV
- MCPyV
- HPV (types not in the current vaccine)

## Development of Vaccines against HIV-associated Malignancies or HIV Infections

### Portfolio Analysis:

- No NCI initiatives to promote vaccine research for HIV or HIV-associated malignancies
- No unsolicited applications on these topics funded by NCI
- NIAID funds most HIV vaccine research
- Some vaccine research is done through the Centers for AIDS Research (CFARs), NIAID funds the majority of the CFAR costs and NCI, NHLBI, NIDA, NIMH, & FIC are co-funding ICs
- Several vaccine studies in NIDCR and FIC

## Development of Vaccines against HIV-associated Malignancies or HIV Infections

### Justification for Use of an RFA:

- Developing vaccines against AIDS associated cancers has been identified as a high priority by the AIDS Malignancy Working Group, which advises the NCI
- The RFA will attract applications from outstanding investigators with a focus in either HIV-associated malignancies or HIV
- Applications will be reviewed by a panel of area experts convened by the NCI Division of Extramural Activities

## Development of Vaccines against HIV-associated Malignancies or HIV Infections

### Administrative:

- Collaboration between Division of Cancer Biology and Office of HIV and AIDS Malignancies
- Funds from ARRA of 2009
- U01 (cooperative agreement) mechanism with a 2 year award
- Budget:
  - \$500K (dc)
- Total Allocation
  - \$10,000,000 per year/\$20,000,000 total
- Expect to fund 20-30 applications
- Follow-on initiatives, exploiting progress from this RFA, are planned.



## Development of Vaccines against HIV-associated Malignancies or HIV Infections

### Evaluation Criteria

- Members of OHAM, and DCB scientific staff will track all grants funded in response to this RFA
- Progress reports and publications will be evaluated by Program and OSPA staff
- Input from the leaders of the extramural scientific and physician/scientist community will also be solicited to comment on the progress accomplished in response to this RFA
- Report will be prepared for presentation to the OD and EC

# American Recovery and Reinvestment Initiatives

- Announcement: NCI Activities to Promote Research Collaborations
- RFA Concept - AIDS Vaccine Program

National Cancer Institute

National Cancer Institute